Merck & Co., Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Merck & Co., Inc. (MRK) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $377.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2024-02-26
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-06-30 was -$5.97B, a 251.23% decline year-over-year.
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-03-31 was $2.83B, a 34.41% decline year-over-year.
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-12-31 was $3.02B, a 21.08% decline year-over-year.
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-09-30 was $3.25B, a 28.83% decline year-over-year.
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was $377.00M, a 97.40% decline from fiscal 2022.
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was $14.53B, a 17.54% increase from fiscal 2021.
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was $12.36B, a 173.23% increase from fiscal 2020.
- Merck & Co., Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2020 was $4.52B, a 19.32% decline from fiscal 2019.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2023-12-31 | $377.00M 10-K · filed 2024-02-26 | |||
| 2023-06-30 | -$5.97B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$3.15B 10-Q · filed 2023-08-07 | -$129.00M derived: sum of 3 quarters · filed 2024-02-26 | $3.12B derived: sum of 4 quarters · filed 2024-02-26 |
| 2023-03-31 | $2.83B 10-Q · filed 2023-05-05 | $5.84B derived: sum of 2 quarters · filed 2024-02-26 | $9.10B derived: sum of 3 quarters · filed 2024-02-26 | $13.04B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-12-31 | $3.02B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $6.27B derived: sum of 2 quarters · filed 2024-02-26 | $10.22B derived: sum of 3 quarters · filed 2024-02-26 | $14.53B 10-K · filed 2024-02-26 |
| 2022-09-30 | $3.25B 10-Q · filed 2022-11-03 | $7.20B derived: sum of 2 quarters · filed 2022-11-03 | $11.51B 10-Q · filed 2022-11-03 | $15.33B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $3.95B 10-Q · filed 2022-08-05 | $8.26B 10-Q · filed 2023-08-07 | $12.08B derived: sum of 3 quarters · filed 2024-02-26 | $16.65B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $4.31B 10-Q · filed 2023-05-05 | $8.13B derived: sum of 2 quarters · filed 2024-02-26 | $12.70B derived: sum of 3 quarters · filed 2024-02-26 | $13.92B derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $3.82B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $8.39B derived: sum of 2 quarters · filed 2024-02-26 | $9.61B derived: sum of 3 quarters · filed 2024-02-26 | $12.36B 10-K · filed 2024-02-26 |
| 2021-09-30 | $4.57B 10-Q · filed 2022-11-03 | $5.79B derived: sum of 2 quarters · filed 2022-11-03 | $8.53B 10-Q · filed 2022-11-03 | $5.92B derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-06-30 | $1.21B 10-Q · filed 2022-08-05 | $3.96B 10-Q · filed 2022-08-05 | $1.35B derived: sum of 3 quarters · filed 2023-02-24 | $3.67B derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-03-31 | $2.75B 10-Q · filed 2022-05-05 | $135.00M derived: sum of 2 quarters · filed 2023-02-24 | $2.46B derived: sum of 3 quarters · filed 2023-02-24 | $4.81B derived: sum of 4 quarters · filed 2023-02-24 |
| 2020-12-31 | -$2.61B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | -$288.00M derived: sum of 2 quarters · filed 2023-02-24 | $2.06B derived: sum of 3 quarters · filed 2023-02-24 | $4.52B 10-K · filed 2023-02-24 |
| 2020-09-30 | $2.33B 10-Q · filed 2021-11-05 | $4.67B derived: sum of 2 quarters · filed 2021-11-05 | $7.14B 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $2.35B 10-Q · filed 2021-08-09 | $4.81B 10-Q · filed 2021-08-09 | ||
| 2019-12-31 | $5.61B 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |